{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:11:07Z","timestamp":1788361867877,"version":"build-2803163510"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["0118530324"],"award-info":[{"award-number":["0118530324"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["2016CFB425"],"award-info":[{"award-number":["2016CFB425"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81200649"],"award-info":[{"award-number":["81200649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.lfs.2022.120543","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T21:00:19Z","timestamp":1649710819000},"page":"120543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review"],"prefix":"10.1016","volume":"300","author":[{"given":"Xie","family":"Lingli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wenfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.120543_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"Supplement_1","key":"10.1016\/j.lfs.2022.120543_bb0010","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2022.120543_bb0015","first-page":"S46","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes. Obes. Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0035","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/dc17-1722","article-title":"Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials","volume":"41","author":"Brouwer","year":"2018","journal-title":"Diabetes Care"},{"issue":"2\u20133","key":"10.1016\/j.lfs.2022.120543_bb0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.mam.2012.05.001","article-title":"SLC9\/NHE gene family, a plasma membrane and organellar family of Na+\/H+ exchangers","volume":"34","author":"Donowitz","year":"2013","journal-title":"Mol. Asp. Med."},{"issue":"14","key":"10.1016\/j.lfs.2022.120543_bb0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.914911","article-title":"Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes","volume":"121","author":"Kohlhaas","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2022.120543_bb0050","first-page":"6","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","author":"Maejima","year":"2020","journal-title":"Front.Cardiovasc.Med."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes","volume":"3","author":"Verma","year":"2018","journal-title":"<sb:contribution><sb:title>JACC Basic Transl.<\/sb:title> <\/sb:contribution><sb:host><sb:issue><sb:series><sb:title>Sci.<\/sb:title><\/sb:series><\/sb:issue><\/sb:host>"},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0070","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1096\/fj.11-195198","article-title":"Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells","volume":"26","author":"Satou","year":"2012","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0075","doi-asserted-by":"crossref","first-page":"F141","DOI":"10.1152\/ajprenal.00465.2016","article-title":"Inflammatory cytokines regulate renal sodium transporters: how, where, and why?","volume":"313","author":"Norlander","year":"2017","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12944-021-01507-8","article-title":"Molecular biochemical aspects of salt (sodium chloride) in inflammation and immune response with reference to hypertension and type 2 diabetes mellitus","volume":"20","author":"Das","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"7446","key":"10.1016\/j.lfs.2022.120543_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature11868","article-title":"Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells","volume":"496","author":"Kleinewietfeld","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.lfs.2022.120543_bb0090","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCIInsight"},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0095","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/ijms18081704","article-title":"The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice","volume":"18","author":"Nakatsu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031164","article-title":"Kidney inflammation, injury and regeneration","volume":"21","author":"Baer","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0105","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40620-020-00845-7","article-title":"SGLT2 inhibitors, sodium and off-target effects: an overview","volume":"34","author":"De Pascalis","year":"2021","journal-title":"J. Nephrol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40620-020-00749-6","article-title":"Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease","volume":"33","author":"\u00d8stergaard","year":"2020","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0125","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0130","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1479164118782872","article-title":"Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial","volume":"15","author":"Takashima","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"12","key":"10.1016\/j.lfs.2022.120543_bb0140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol. Ther."},{"issue":"17","key":"10.1016\/j.lfs.2022.120543_bb0145","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.lfs.2022.120543_bb0150","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14562","article-title":"A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors","volume":"24","author":"Ekanayake","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0165","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0170","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/dom.14503","article-title":"Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation","volume":"23","author":"Kim","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0175","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0180","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \"Thrifty Substrate\" hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.lfs.2022.120543_bb0185","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0190","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0341-5","article-title":"LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial","volume":"15","author":"Masmiquel","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0200","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/dom.12971","article-title":"Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes","volume":"19","author":"Gummesson","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0205","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2022.120543_bb0210","first-page":"S65","article-title":"Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0215","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2337\/dc14-1630","article-title":"Weight management in type 2 diabetes: current and emerging approaches to treatment","volume":"38","author":"Van Gaal","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2022.120543_bb0220","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0225","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0230","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J. Diabetes Investig."},{"issue":"22","key":"10.1016\/j.lfs.2022.120543_bb0235","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"9896","key":"10.1016\/j.lfs.2022.120543_bb0250","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0255","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J.Clin.Endocrinol.Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0265","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.01.001","article-title":"Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"41","author":"Wang","year":"2019","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0270","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40261-017-0580-6","article-title":"Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus","volume":"38","author":"Kurinami","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"Plos One"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0290","first-page":"121","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0295","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0300","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2022.120543_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARalpha in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2022.120543_bb0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2016.02.134","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","volume":"212","author":"Ghosh","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2022.120543_bb0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"Ebiomedicine"},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8110514","article-title":"SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: a novel mechanism for Beiging","volume":"8","author":"Matthews","year":"2020","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0330","first-page":"1113","article-title":"SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids","volume":"14","author":"Filippas-Ntekouan","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13098-021-00652-5","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus","volume":"13","author":"Jiang","year":"2021","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.lfs.2022.120543_bb0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2021.01.063","article-title":"Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: association with a slight increase in high-density lipoprotein cholesterol","volume":"331","author":"Jojima","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2022.120543_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"Sanchez-Garcia","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0355","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0360","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","article-title":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","volume":"11","author":"Bays","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0365","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes. Obes. Metab."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0370","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0375","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0380","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J.Clin.Endocrinol.Metab."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0385","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0390","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0395","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0400","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0405","first-page":"211","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet DiabetesEndocrinol."},{"issue":"13","key":"10.1016\/j.lfs.2022.120543_bb0410","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0415","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0420","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am. J. Physiol.RenalPhysiol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0425","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sj\u00f6str\u00f6m","year":"2015","journal-title":"DiabetesVasc.Dis.Res."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0430","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0435","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0440","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure:a systematic review and meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0445","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0450","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors and blood pressure decrease","volume":"33","author":"Imprialos","year":"2015","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0455","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"16","key":"10.1016\/j.lfs.2022.120543_bb0460","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0465","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/00325481.2018.1423852","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"130","author":"Guthrie","year":"2018","journal-title":"Postgrad. Med."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0470","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"Plos One"},{"issue":"1\u20133","key":"10.1016\/j.lfs.2022.120543_bb0480","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0485","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE \u2212\/\u2212 mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"Plos One"},{"key":"10.1016\/j.lfs.2022.120543_bb0495","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"16","key":"10.1016\/j.lfs.2022.120543_bb0500","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0505","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0510","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/HJH.0000000000001907","article-title":"Diabetic patients with essential hypertension treated with amlodipine","volume":"37","author":"Ramirez","year":"2019","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.lfs.2022.120543_bb0515","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0520","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"29","key":"10.1016\/j.lfs.2022.120543_bb0525","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2174\/1381612043382756","article-title":"Sympathetic and baroreflex function in hypertension: implications for current and new drugs","volume":"10","author":"Grassi","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2022.120543_bb0530","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1081\/CEH-100001201","article-title":"Antihypertensive drugs and sympathetic nervous system","volume":"23","author":"Rabbia","year":"2001","journal-title":"Clin. Exp. Hypertens."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0535","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-017-0750-1","article-title":"Factors responsible for obesity-related hypertension","volume":"19","author":"Lim","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.lfs.2022.120543_bb0540","first-page":"9","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","author":"Wan","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pcad.2009.05.003","article-title":"Heart rate as a risk factor for cardiovascular disease","volume":"52","author":"Perret-Guillaume","year":"2009","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0550","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0555","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0560","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","volume":"20","author":"Briasoulis","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0565","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/hr.2017.14","article-title":"Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats","volume":"40","author":"Yoshikawa","year":"2017","journal-title":"Hypertens. Res."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0570","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review","volume":"8","author":"Sharaf El Din","year":"2017","journal-title":"J. Adv. Res."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0575","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am. J. Physiol.RenalPhysiol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0580","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0585","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.sjbs.2018.11.013","article-title":"Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis","volume":"26","author":"Xin","year":"2019","journal-title":"Saudi J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0590","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0595","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0600","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13300-014-0063-1","article-title":"The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review","volume":"5","author":"McGill","year":"2014","journal-title":"Diabetes Ther."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0605","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0610","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0615","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0620","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0625","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4,placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0630","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials","volume":"37","author":"Coelho","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0645","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes. Obes. Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.EJ18-0217","article-title":"Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results)","volume":"66","author":"Tabuchi","year":"2019","journal-title":"Endocr. J."},{"issue":"9","key":"10.1016\/j.lfs.2022.120543_bb0655","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.lfs.2022.120543_bb0660","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0665","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0670","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J. Diabetes Investig."},{"issue":"10","key":"10.1016\/j.lfs.2022.120543_bb0675","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label,active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0680","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0685","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18433\/jpps29831","article-title":"Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"21","author":"Li","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0690","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2022.120543_bb0695","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: ex quo et quo vadimus?","volume":"98","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0700","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCIInsight"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0705","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","article-title":"SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes","volume":"44","author":"Bajaj","year":"2018","journal-title":"Diabetes Metab."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0710","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s42000-018-0021-9","article-title":"The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)","volume":"17","author":"Iogna Prat","year":"2018","journal-title":"Hormones"},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0715","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0720","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0725","doi-asserted-by":"crossref","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","article-title":"Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes","volume":"313","author":"Tang","year":"2017","journal-title":"Am. J. Physiol.Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0730","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J. Diabetes Investig."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0735","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized,double-blind crossover trial","volume":"44","author":"Op","year":"2021","journal-title":"Diabetes Care"},{"issue":"7\u20138","key":"10.1016\/j.lfs.2022.120543_bb0740","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.clinbiochem.2015.12.010","article-title":"High serum uric acid and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"49","author":"Zhou","year":"2016","journal-title":"Clin. Biochem."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0745","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0750","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0755","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/dom.12923","article-title":"Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity","volume":"19","author":"Joannides","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0760","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in Zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O'Brien","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2022.120543_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108916","article-title":"Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin","author":"Jinnouchi","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0770","first-page":"415","article-title":"Glucose toxicity","volume":"13","author":"Yki-Jarvinen","year":"1992","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0775","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"<sb:contribution><sb:title>JACC Basic Transl.<\/sb:title> <\/sb:contribution><sb:host><sb:issue><sb:series><sb:title>Sci.<\/sb:title><\/sb:series><\/sb:issue><\/sb:host>"},{"issue":"S120","key":"10.1016\/j.lfs.2022.120543_bb0780","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"79","author":"List","year":"2011","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0785","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbrc.2015.10.109","article-title":"Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic \u03b2-cells in obese type 2 diabetic db\/db mice","volume":"470","author":"Okauchi","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0790","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bbrc.2015.10.038","article-title":"Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key \u03b2-cell factors under diabetic conditions","volume":"467","author":"Shimo","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7086","key":"10.1016\/j.lfs.2022.120543_bb0795","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nature04634","article-title":"Reactive oxygen species have a causal role in multiple forms of insulin resistance","volume":"440","author":"Houstis","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2022.120543_bb0800","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","article-title":"Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus","volume":"149","author":"Koike","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0805","first-page":"365","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"TrendsEndocrinol.Metab."},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0810","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"52","key":"10.1016\/j.lfs.2022.120543_bb0815","doi-asserted-by":"crossref","first-page":"50230","DOI":"10.1074\/jbc.M200958200","article-title":"Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle","volume":"277","author":"Yu","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0820","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/0026-0495(95)90135-3","article-title":"Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats","volume":"44","author":"Sztalryd","year":"1995","journal-title":"Metabolism"},{"issue":"7285","key":"10.1016\/j.lfs.2022.120543_bb0825","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0830","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/ijms20051190","article-title":"Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives","volume":"20","author":"Yanai","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0835","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.14859","article-title":"Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice","volume":"177","author":"Chiang","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0840","article-title":"The role of adipokines in skeletal muscle inflammation and insulin sensitivity","volume":"15","author":"Nicholson","year":"2018","journal-title":"J.Inflamm.(Lond., Engl.)"},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb0845","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0958-2441","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Horm. Metab. Res."},{"issue":"29","key":"10.1016\/j.lfs.2022.120543_bb0850","doi-asserted-by":"crossref","first-page":"30817","DOI":"10.1074\/jbc.M402367200","article-title":"Insulin\/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity","volume":"279","author":"Tsuchida","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0855","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cardiores.2006.10.009","article-title":"Adiponectin actions in the cardiovascular system","volume":"74","author":"Hopkins","year":"2007","journal-title":"Cardiovasc. Res."},{"issue":"11","key":"10.1016\/j.lfs.2022.120543_bb0860","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1161\/01.CIR.102.11.1296","article-title":"Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway","volume":"102","author":"Ouchi","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2022.120543_bb0865","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0870","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jphs.2017.10.006","article-title":"Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats","volume":"137","author":"Li","year":"2018","journal-title":"J. Pharmacol. Sci."},{"issue":"13","key":"10.1016\/j.lfs.2022.120543_bb0875","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0880","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2796.2002.00932.x","article-title":"Diabetes and advanced glycation endproducts","volume":"251","author":"Vlassara","year":"2002","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"Plos One"},{"issue":"10","key":"10.1016\/j.lfs.2022.120543_bb0895","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diabetes.51.10.2929","article-title":"Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0900","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/oby.21436","article-title":"TNF-alpha downregulates CIDEC via MEK\/ERK pathway in human adipocytes","volume":"24","author":"Tan","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0905","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-019-0910-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial","volume":"18","author":"Bonora","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb0910","first-page":"384","article-title":"Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis","volume":"22","author":"Ashrafi","year":"2019","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0920","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice","volume":"5","author":"Nakano","year":"2015","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0925","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0930","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/JOE-20-0354","article-title":"SGLT2-i improves markers of islet endothelial cell function in db\/db diabetic mice","volume":"248","author":"Hogan","year":"2021","journal-title":"J. Endocrinol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0935","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2022.120543_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154324","article-title":"Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice","volume":"111","author":"Wei","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0945","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3892\/ijmm.2015.2207","article-title":"Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets","volume":"36","author":"Huang","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.lfs.2022.120543_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154232","article-title":"Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and \u03b2-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats","volume":"107","author":"Guo","year":"2020","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.lfs.2022.120543_bb0955","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/dom.14149","article-title":"The effects of ertugliflozin on \u03b2-cell function: pooled analysis from four phase 3 randomized controlled studies","volume":"22","author":"Gallo","year":"2020","journal-title":"Diabetes. Obes. Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0960","article-title":"Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic \u03b2 cells in diabetic db\/db mice","volume":"11","author":"Fushimi","year":"2021","journal-title":"Sci. Rep.UK"},{"issue":"2","key":"10.1016\/j.lfs.2022.120543_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258054","article-title":"SGLT2 inhibitors therapy protects glucotoxicity-induced \u03b2-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress","volume":"17","author":"Shyr","year":"2022","journal-title":"Plos One"},{"issue":"12","key":"10.1016\/j.lfs.2022.120543_bb0970","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes. Obes. Metab."},{"issue":"6","key":"10.1016\/j.lfs.2022.120543_bb0975","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2022.120543_bb0980","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2022.120543_bb0985","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.lfs.2022.120543_bb0990","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3170","article-title":"Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis","volume":"35","author":"Li","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"5","key":"10.1016\/j.lfs.2022.120543_bb0995","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","article-title":"Risk of bone fracture associated with sodium\u2013glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"45","author":"Cheng","year":"2019","journal-title":"Diabetes Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb1000","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J.Clin.Endocrinol.Metab."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb1005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J.Clin.Endocrinol.Metab."},{"issue":"8","key":"10.1016\/j.lfs.2022.120543_bb1010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health","volume":"14","author":"Blau","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb1015","first-page":"8","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet DiabetesEndocrinol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120543_bb1020","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-017-0853-8","article-title":"Should side effects influence the selection of antidiabetic therapies in type 2 diabetes?","volume":"17","author":"Grunberger","year":"2017","journal-title":"Curr. Diabetes Rep."},{"issue":"1","key":"10.1016\/j.lfs.2022.120543_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:02:29Z","timestamp":1758402149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":204,"alternative-id":["S0024320522002430"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120543","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120543"}}